Sponsor or institution

Clinical trials and research at Dana-Farber Cancer Institute

• 150Clinical trials
• 1Country

Newest trials

All recruiting trials (150)

• Botensilimab + Balstilimab before surgery for early MSS rectal cancer

  This study tests whether giving a single dose of botensilimab followed by balstilimab can shrink MSS/pMMR early rectal tumors so some patients can avoid surgery.

  Recruiting at 2 sites Phase 2 Dana-Farber Cancer Institute · Boston, Massachusetts and 2 other locations · NCT07735624

• LLM-generated serious illness summaries for cancer patients getting hospitalized

  This trial tests whether sending an AI-generated serious-illness summary to a patient’s clinicians at hospital admission helps reduce hospital days for adults with solid tumors.

  Recruiting at 2 sites Dana-Farber Cancer Institute · Boston, Massachusetts and 1 other locations · NCT07735442

• Wearable cooling device to ease hot flashes in men on ADT for prostate cancer

  A randomized test to see if the Embr Wave wearable can reduce hot flashes in men with prostate cancer on androgen deprivation therapy.

  Recruiting Dana-Farber Cancer Institute · Boston, Massachusetts · NCT07729150

• Clonal Hematopoiesis Effects with Chemo and Radiation in Solid Cancers

  This study tests whether clonal hematopoiesis affects outcomes for adults with solid cancers who are receiving chemotherapy or radiation.

  Recruiting Dana-Farber Cancer Institute · Boston, Massachusetts · NCT07675967

• AYA Sarcoma Survivors: Personalized Exercise Program Pilot

  This pilot tests a personalized 12-week exercise program for adolescents and young adults with sarcoma to see if a triage tool can connect them with the right rehabilitation and exercise services.

  Recruiting at 3 sites Dana-Farber Cancer Institute · Boston, Massachusetts and 2 other locations · NCT07662239

• Isatuximab, Iberdomide, Bortezomib, and Dexamethasone Induction in New Myeloma, Followed by Adaptive Consolidation and Maintenance for Transplant-Eligible Patients

  This study tests a combination therapy for newly diagnosed, transplant-eligible multiple myeloma patients to see if risk- and response-guided maintenance and consolidation can improve outcomes.

  Recruiting Phase 3 Dana-Farber Cancer Institute · Boston, Massachusetts and 2 other locations · NCT07624513

• SMARCA4/2 Inhibitor for POU2F3-Positive Small Cell Lung Cancer

  This trial tests FHD-286, a SMARCA4/2 inhibitor, in people with POU2F3-expressing small cell lung cancer who have already had platinum therapy.

  Recruiting Phase 2 Dana-Farber Cancer Institute · Boston, Massachusetts · NCT07551635

• Acupuncture and Exercise for EV-Pembro–Induced Peripheral Neuropathy

  This study tests whether adding acupuncture to a gentle virtual exercise program helps reduce chemotherapy-induced nerve problems in bladder cancer patients taking EV and pembrolizumab.

  Recruiting Dana-Farber Cancer Institute · Boston, Massachusetts · NCT07548476

• Support tool for women with HR+ breast cancer on long-term endocrine therapy

  This study tests a SHIELD web- and app-based portal to help women with hormone receptor–positive breast cancer manage symptoms while on long-term endocrine treatment.

  Recruiting Dana-Farber Cancer Institute · Boston, Massachusetts · NCT07482384

• Elacestrant for ER-positive uterine sarcomas

  This trial tests whether the oral drug elacestrant can slow or stop growth in people with advanced estrogen receptor–positive uterine sarcomas.

  Recruiting Phase 2 Dana-Farber Cancer Institute · Boston, Massachusetts · NCT07467772

• Ficerafusp alfa plus pembrolizumab before surgery for resectable head and neck squamous cell carcinoma

  This trial will test whether giving ficerafusp alfa together with pembrolizumab before surgery helps people with PD‑L1–positive, resectable, high‑risk head and neck squamous cell carcinoma.

  Recruiting at 2 sites Phase 2 Dana-Farber Cancer Institute · Boston, Massachusetts and 1 other locations · NCT07465276

• Comparing biotin-labeled and 51‑chromium–labeled red blood cells after autologous transfusion

  This test tries to see if biotin-labeled red blood cells can replace radioactive 51Cr-labeled cells to measure red blood cell recovery and survival in healthy adults who donate and receive their own blood.

  Recruiting Phase 1 Dana-Farber Cancer Institute · Cincinnati, Ohio and 1 other locations · NCT07446647

• Triple-drug approach for AML using eganelisib with azacitidine and venetoclax

  This early-stage trial tests whether adding eganelisib to azacitidine and venetoclax can be safe and show signs of benefit in adults with acute myeloid leukemia.

  Recruiting at 2 sites Phase 1 Dana-Farber Cancer Institute · Boston, Massachusetts and 1 other locations · NCT07439211

• Pemigatinib for advanced SDH‑deficient GIST

  This trial will try the oral drug pemigatinib in adults with advanced SDH‑deficient GIST to see if it controls tumor growth and what side effects occur.

  Recruiting Phase 2 Dana-Farber Cancer Institute · Boston, Massachusetts · NCT07434843

• Cosibelimab for tough CSCC in kidney transplant recipients or blood cancers

  This trial tests cosibelimab in people with advanced cutaneous squamous cell carcinoma who have a kidney transplant or certain blood cancers to see if it is safe and helpful for them.

  Recruiting at 2 sites Phase 4 Dana-Farber Cancer Institute · Boston, Massachusetts and 1 other locations · NCT07426484

• Precise Exercise Regimen for Cancer Care: a small pilot in stage II/III NSCLC

  This pilot tests the PERCC exercise program to see if it’s feasible for adults with stage II–III non-small cell lung cancer who are planned for neoadjuvant therapy and surgery.

  Recruiting Dana-Farber Cancer Institute · Boston, Massachusetts · NCT07412041

• Neoadjuvant HIF-2α inhibitor with or without PD-1 antibody for resectable clear cell kidney cancer

  This trial tests whether casdatifan alone or combined with zimberelimab can shrink tumors in people with resectable clear cell kidney cancer before surgery.

  Recruiting at 2 sites Phase 2 Dana-Farber Cancer Institute · Boston, Massachusetts and 2 other locations · NCT07397611

• B7-H3 CAR T cells for recurrent brain tumors in kids and young adults

  This early-phase trial tests a personalized CAR T-cell therapy called B7-H3 CAR T for children and young adults with recurrent or progressive brain tumors.

  Recruiting at 2 sites Phase 1 Dana-Farber Cancer Institute · Boston, Massachusetts and 1 other locations · NCT07390539

• B7-H3 CAR T cells for relapsed or refractory solid tumors in children and young adults

  This study tests a new B7-H3 CAR T cell therapy to see if it is safe and can help kids and young adults whose solid tumors have come back or stopped responding to standard treatments.

  Recruiting Phase 1 Dana-Farber Cancer Institute · Boston, Massachusetts · NCT07358260

• Dose-modified cancer therapy for people with Duffy null phenotype

  This pilot study tests whether using Duffy null-specific dosing guidelines can reduce dose changes and prevent neutropenic fever in people with Duffy null who are treated for multiple myeloma or triple negative breast cancer.

  Recruiting Phase 1 Dana-Farber Cancer Institute · Boston, Massachusetts and 1 other locations · NCT07341867

• On-Trac: Online training to manage anxiety after cancer

  This program will try an online CBT- and ACT-based education plus brief coaching to help adult cancer survivors manage ongoing anxiety.

  Recruiting Dana-Farber Cancer Institute · Boston, Massachusetts · NCT07305740

• Lifileucel (TIL) plus chemotherapy and IL-2 for advanced cutaneous squamous cell and Merkel cell carcinoma

  This trial will try lifileucel (tumor-infiltrating lymphocytes) combined with lymphodepleting chemotherapy and interleukin-2 in adults with unresectable or metastatic cutaneous squamous cell carcinoma or Merkel cell carcinoma who have previously received immunotherapy.

  Recruiting Phase 2 Dana-Farber Cancer Institute · Boston, Massachusetts · NCT07288073

• AI-driven tool to match cancer trials using EHRs

  A cancer trial matching tool uses artificial intelligence with electronic health records to help doctors find and suggest suitable trials for adult cancer patients at Dana-Farber.

  Recruiting Dana-Farber Cancer Institute · Boston, Massachusetts · NCT07232043

• ALL Backbone in AYAs

  Aims to see if a chemotherapy regimen can safely and effectively treat newly diagnosed Philadelphia chromosome-negative ALL in adolescents and young adults.

  Recruiting Phase 2 Dana-Farber Cancer Institute · Boston, Massachusetts · NCT07227584

• Capecitabine with or without elacestrant for ER-positive advanced breast cancer

  This trial will try adding elacestrant to capecitabine to see if it helps people with ER-positive, HER2-negative advanced breast cancer that stopped responding to CDK4/6 inhibitors.

  Recruiting Phase 2 Dana-Farber Cancer Institute · Boston, Massachusetts · NCT07222215

• Elacestrant plus trastuzumab deruxtecan for HR-positive, HER2-low or HER2-ultralow metastatic breast cancer after CDK4/6 and endocrine therapy

  This trial tests whether combining elacestrant with trastuzumab deruxtecan helps people with HR-positive, HER2-low or HER2-ultralow metastatic breast cancer that progressed after CDK4/6 inhibitor and endocrine treatment.

  Recruiting Phase 1/2 Dana-Farber Cancer Institute · Boston, Massachusetts · NCT07198724

• Targeting measurable residual AML with tagraxofusp plus azacitidine and venetoclax

  This trial tests whether adding tagraxofusp to azacitidine and venetoclax can safely help control measurable residual acute myeloid leukemia (AML) in adults who are in remission but still have detectable disease.

  Recruiting at 2 sites Phase 1/2 Dana-Farber Cancer Institute · Boston, Massachusetts and 1 other locations · NCT07148180

• Individualized surveillance mammography for older breast cancer survivors

  This project tests a shared decision-making toolkit to help breast cancer survivors aged 80 and older decide whether to continue routine surveillance mammograms.

  Recruiting Phase 2 Dana-Farber Cancer Institute · Boston, Massachusetts · NCT07123649

• Combining sasanlimab, palbociclib, and axitinib for metastatic kidney cancer

  This test tries a combination of sasanlimab, palbociclib, and axitinib in people with advanced or metastatic clear cell or translocation renal cell carcinoma to see if it works and is safe.

  Recruiting at 2 sites Phase 2 Dana-Farber Cancer Institute · Boston, Massachusetts and 1 other locations · NCT07123090

• Germline testing for inherited risk of myeloid blood cancers

  This research will test whether a germline genetic test (MyeloGen Gene Panel) can find inherited changes linked to myeloid blood cancers in adults who have been diagnosed.

  Recruiting Dana-Farber Cancer Institute · Boston, Massachusetts · NCT07112287

• Cryocompression to prevent taxane-induced nerve damage in the arms and legs.

  This study tests whether cooling and pressure applied to the arms and legs during taxane chemotherapy can prevent or reduce numbness, pain, or weakness from peripheral neuropathy in adults with breast or gynecologic cancer.

  Recruiting Dana-Farber Cancer Institute · Boston, Massachusetts · NCT07064798

• Mosunetuzumab to clear minimal residual disease in CLL and SLL.

  This trial will try mosunetuzumab, alone or with a BTK inhibitor, to clear minimal residual disease in people with chronic lymphocytic leukemia or small lymphocytic lymphoma.

  Recruiting at 2 sites Phase 1/2 Dana-Farber Cancer Institute · Boston, Massachusetts and 1 other locations · NCT07052695

• Prolonged Naxitamab with irinotecan, temozolomide, and sargramostim for relapsed or refractory neuroblastoma

  This trial will test whether giving the immunotherapy Naxitamab more slowly, along with irinotecan, temozolomide, and sargramostim, reduces infusion side effects for people with relapsed or refractory neuroblastoma.

  Recruiting at 2 sites Phase 1 Dana-Farber Cancer Institute · Boston, Massachusetts and 1 other locations · NCT07027748

• Expanded regulatory T cells plus low-dose IL-2 for steroid-refractory chronic GVHD

  This trial tests whether a single dose of expanded regulatory T cells given with daily low-dose IL-2 can help children and adults with chronic GVHD that did not improve with steroids.

  Recruiting Phase 1 Dana-Farber Cancer Institute · Boston, Massachusetts · NCT06991361

• Pacritinib for relapsed or refractory Waldenström macroglobulinemia

  This trial will test whether the oral drug pacritinib can safely reduce disease and symptoms in adults whose Waldenström macroglobulinemia has returned or did not respond to prior treatment.

  Recruiting Phase 2 Dana-Farber Cancer Institute · Boston, Massachusetts · NCT06986174

• DT2216 with weekly paclitaxel for platinum-resistant ovarian cancer

  We are testing whether adding DT2216 to weekly paclitaxel is safe and tolerable for people with recurrent platinum‑resistant ovarian cancer.

  Recruiting at 2 sites Phase 1 Dana-Farber Cancer Institute · Boston, Massachusetts and 2 other locations · NCT06964009

• ACT Lung Health Program to help Chinese and Korean American smokers quit

  This trial tests a counseling and educational program to help Chinese and Korean American smokers at high risk for lung cancer quit smoking.

  Recruiting at 2 sites Dana-Farber Cancer Institute · Boston, Massachusetts and 1 other locations · NCT06945120

• Toripalimab plus carboplatin and docetaxel before surgery for sinonasal cancer

  This study tests whether giving toripalimab with carboplatin and docetaxel before surgery helps people with locally advanced sinonasal cancers.

  Recruiting at 2 sites Phase 2 Dana-Farber Cancer Institute · Boston, Massachusetts and 1 other locations · NCT06940180

• Program to support patients with advanced gastrointestinal and gynecologic cancers

  This study is testing a new support program to see if it can help people with advanced gastrointestinal and gynecologic cancers feel better and need less hospital care.

  Recruiting at 2 sites Dana-Farber Cancer Institute · Boston, Massachusetts and 1 other locations · NCT06936878

• Breaking up long sitting periods to improve heart health and reduce chemo side effects in adults with lymphoma on R-CHOP or POLA-R-CHP

  This trial will test whether a 12-week program that interrupts long periods of sitting helps newly diagnosed adults with lymphoma receiving R-CHOP or POLA-R-CHP chemotherapy improve heart health and reduce chemotherapy side effects.

  Recruiting Dana-Farber Cancer Institute · Boston, Massachusetts · NCT06923397

• Testing a web application to help patients with acute leukemia

  This study is testing a new web app to see if it can help people with acute leukemia find and join clinical trials more easily.

  Recruiting Dana-Farber Cancer Institute · Boston, Massachusetts · NCT06907797

• Bendamustine–Rituximab–Cytarabine plus Zanubrutinib induction followed by zanubrutinib/rituximab with or without sonrotoclax maintenance for newly diagnosed mantle cell lymphoma

  This trial tests whether giving zanubrutinib with a bendamustine‑rituximab‑cytarabine induction and then continuing zanubrutinib with rituximab, with or without sonrotoclax, helps people with newly diagnosed mantle cell lymphoma stay in remission longer.

  Recruiting at 4 sites Phase 2 Dana-Farber Cancer Institute · Phoenix, Arizona and 6 other locations · NCT06854003

• Supportive care intervention for low-income children with high-risk neuroblastoma

  This study is testing a new supportive care program for low-income children with high-risk neuroblastoma to see if it helps them and their families feel better during treatment.

  Recruiting at 6 sites Dana-Farber Cancer Institute · Hartford, Connecticut and 5 other locations · NCT06831552

• Evaluating Ivonescimab for advanced salivary gland cancers

  This study is testing a new treatment called Ivonescimab to see if it can help people with advanced salivary gland cancers feel better and improve their health.

  Recruiting at 2 sites Phase 2 Dana-Farber Cancer Institute · Boston, Massachusetts and 1 other locations · NCT06805617

• Early treatment for high-risk Clonal Cytopenia of Undetermined Significance

  This study is testing if an early treatment with a new oral medication can help people with high-risk Clonal Cytopenia of Undetermined Significance feel better and stay healthier over three years.

  Recruiting Early Phase 1 Dana-Farber Cancer Institute · Boston, Massachusetts · NCT06802146

• Blood test for screening EGFR positive lung cancer in at-risk populations

  This study is testing a new blood test to see if it can help find EGFR positive lung cancer early in healthy people from East Asian and Latinx backgrounds who are at risk and can't have regular screenings.

  Recruiting Dana-Farber Cancer Institute · Boston, Massachusetts and 5 other locations · NCT06716580

• Reducing fatigue in adults with ovarian cancer on PARP inhibitors

  This study is testing a tele-health program called REVITALIZE to see if it can help reduce fatigue and improve daily life for adults with ovarian cancer who are taking PARP inhibitors.

  Recruiting at 6 sites Dana-Farber Cancer Institute · Aurora, Colorado and 5 other locations · NCT06710548

• Testing a new drug combination for treating relapsed or refractory sarcomas in adolescents and young adults

  This study is testing a new combination of drugs to see if it can help adolescents and young adults with tough-to-treat sarcomas feel better and improve their chances of recovery.

  Recruiting Phase 1/2 Dana-Farber Cancer Institute · Boston, Massachusetts and 2 other locations · NCT06709495

• Using Belzutifan to treat recurrent clear cell ovarian carcinoma

  This study is testing if a new targeted therapy called Belzutifan can help people with recurrent clear cell ovarian cancer feel better and manage their disease.

  Recruiting at 2 sites Phase 2 Dana-Farber Cancer Institute · Boston, Massachusetts and 1 other locations · NCT06677190

• Injecting flu vaccine into skin cancer tumors before surgery

  This study is testing whether injecting the flu vaccine into skin cancer tumors before surgery can help boost the body's immune response against the cancer in people with cutaneous squamous cell carcinoma.

  Recruiting at 2 sites Early Phase 1 Dana-Farber Cancer Institute · Boston, Massachusetts and 1 other locations · NCT06664151

• Roginolisib with venetoclax and rituximab for relapsed or refractory CLL

  This trial will test whether adding roginolisib to the standard venetoclax plus rituximab treatment helps people with relapsed or refractory CLL get deeper and longer remissions.

  Recruiting Phase 1/2 Dana-Farber Cancer Institute · Boston, Massachusetts · NCT06644183

• Using RP2 to prevent oral cancer in high-risk patients

  This study is testing if an injected immune therapy called RP2 can help prevent oral cancer in patients who are at high risk due to precancerous conditions.

  Recruiting at 2 sites Phase 2 Dana-Farber Cancer Institute · Boston, Massachusetts and 1 other locations · NCT06623110

• Exercise and nutrition program for older cancer survivors and their support person

  This study will see if a 6-month virtually supervised versus unsupervised home exercise and healthy diet program helps older cancer survivors and their support person improve thinking and physical function.

  Recruiting at 2 sites Dana-Farber Cancer Institute · Miami, Florida and 1 other locations · NCT06623097

• Improving heart health through nutrition for childhood cancer survivors

  This study is testing a nutrition program to see if it can help childhood cancer survivors improve their heart health.

  Recruiting at 2 sites Dana-Farber Cancer Institute · Boston, Massachusetts and 1 other locations · NCT06609473

• Evaluating elranatamab for patients with relapsed or refractory AL amyloidosis

  This study is testing a new treatment called elranatamab to see if it can help people with relapsed or refractory AL amyloidosis feel better and manage their condition.

  Recruiting at 5 sites Phase 1/2 Dana-Farber Cancer Institute · New Haven, Connecticut and 4 other locations · NCT06569147

• Prehabilitation program for patients with rectal cancer

  This study is testing a prehabilitation program to see if it helps people with rectal cancer feel better before surgery compared to standard care.

  Recruiting at 2 sites Dana-Farber Cancer Institute · Boston, Massachusetts and 1 other locations · NCT06565052

• Combination treatment for relapsed or refractory follicular lymphoma

  This study is testing a new combination of three medications to see if it can help people with relapsed or refractory follicular lymphoma feel better.

  Recruiting at 3 sites Phase 2 Dana-Farber Cancer Institute · Boston, Massachusetts and 2 other locations · NCT06563596

• Testing Troriluzole for recurrent glioblastoma treatment

  This study is testing if Troriluzole can help people with recurrent glioblastoma feel better when given before and after surgery compared to just after surgery.

  Recruiting at 3 sites Early Phase 1 Dana-Farber Cancer Institute · Boston, Massachusetts and 2 other locations · NCT06552260

• Testing a new communication tool for ovarian cancer patients and their caregivers

  This study is testing a new communication tool to see if it helps ovarian cancer patients, their caregivers, and doctors work better together in planning care.

  Recruiting Dana-Farber Cancer Institute · Boston, Massachusetts · NCT06543537

• Treatment for HER2-negative metastatic breast cancer using two investigational drugs

  This study is testing if using two new drugs one after the other can help people with HER2-negative metastatic breast cancer live longer and feel better.

  Recruiting at 10 sites Phase 2 Dana-Farber Cancer Institute · Birmingham, Alabama and 10 other locations · NCT06533826

• Evaluating a blood test for early cancer detection in military veterans

  This study is testing a new blood test to see if it can help find different types of cancer early in military veterans.

  Recruiting Dana-Farber Cancer Institute · Boston, Massachusetts · NCT06523868

• Combining Elotuzumab and Iberdomide with Dexamethasone for Relapsed Multiple Myeloma

  This study is testing a new combination of Elotuzumab, Iberdomide, and Dexamethasone to see if it helps people with relapsed multiple myeloma who have already tried another treatment.

  Recruiting at 2 sites Phase 1 Dana-Farber Cancer Institute · Boston, Massachusetts and 2 other locations · NCT06518551

• Understanding the in-home hospice experience for breast cancer patients

  This study looks at how to improve hospice care for breast cancer patients at home by checking in with them and their caregivers through telehealth to see what works best.

  Recruiting Dana-Farber Cancer Institute · Boston, Massachusetts · NCT06507930

• Testing axatilimab with olaparib for advanced HER2-negative breast cancer with specific gene mutations

  This study is testing a new drug called axatilimab combined with olaparib to see if it helps people with advanced HER2-negative breast cancer who have specific gene mutations.

  Recruiting at 2 sites Phase 1 Dana-Farber Cancer Institute · Boston, Massachusetts and 1 other locations · NCT06488378

• Home blood transfusions for people with advanced blood cancers in hospice

  The study will test whether offering home blood transfusions to adults with advanced or relapsed blood cancers who are eligible for hospice helps improve quality of life, mood, and end-of-life care.

  Recruiting at 2 sites Dana-Farber Cancer Institute · Boston, Massachusetts and 1 other locations · NCT06487247

• Combining Pembrolizumab with chemotherapy for newly diagnosed brain lymphoma

  This study is testing if combining Pembrolizumab with chemotherapy can help people who have just been diagnosed with brain lymphoma feel better and improve their treatment outcomes.

  Recruiting at 2 sites Phase 1 Dana-Farber Cancer Institute · Boston, Massachusetts and 1 other locations · NCT06475235

• Enhancing diversity in clinical trial enrollment through community engagement

  This study is trying to see if getting feedback from patients and community members can help make clinical trials for blood cancer and leukemia more inclusive and diverse.

  Recruiting Dana-Farber Cancer Institute · Boston, Massachusetts · NCT06469307

• Improving sleep for children undergoing stem cell transplants

  This study is testing a program to help children getting stem cell transplants sleep better in the hospital by giving families tools to create a more restful environment.

  Recruiting at 2 sites Dana-Farber Cancer Institute · Boston, Massachusetts and 1 other locations · NCT06468618

• Evaluating a blood test for early cancer detection in high-risk individuals

  This study is testing a blood test that aims to find different types of cancer early in people who are at higher risk for developing the disease.

  Recruiting Dana-Farber Cancer Institute · Boston, Massachusetts · NCT06450171

• Sequential therapy for HER2-positive metastatic breast cancer

  This study is testing whether giving a specific order of HER2-targeted drugs can help people with HER2-positive metastatic breast cancer feel better and live longer.

  Recruiting Phase 2 Dana-Farber Cancer Institute · Boston, Massachusetts · NCT06439693

• Investigating Azenosertib for Uterine Serous Carcinoma

  This study is testing a new drug called Azenosertib to see if it can help people with persistent or recurring uterine serous carcinoma.

  Recruiting at 2 sites Phase 2 Dana-Farber Cancer Institute · Boston, Massachusetts and 1 other locations · NCT06369155

• Comparing Letrozole/Abemaciclib to Pembrolizumab for Endometrial Cancer Maintenance

  This study is testing whether a combination of letrozole and abemaciclib can help people with advanced or recurring endometrial cancer feel better compared to taking pembrolizumab alone after their initial chemotherapy.

  Recruiting at 6 sites Phase 2 Dana-Farber Cancer Institute · Aurora, Colorado and 7 other locations · NCT06366347

• Fixed-duration treatment for chronic lymphocytic leukemia with pirtobrutinib and obinutuzumab

  This study is testing a year-long treatment combining two medications, pirtobrutinib and obinutuzumab, to see if it helps people with chronic lymphocytic leukemia feel better.

  Recruiting at 4 sites Phase 2 Dana-Farber Cancer Institute · Scarborough, Maine and 3 other locations · NCT06333262

• CIML NK cell therapy for recurrent ovarian cancer

  This study is testing a new treatment using special immune cells to see if it can help people with recurrent high-grade ovarian cancer feel better and improve their health.

  Recruiting Phase 1 Dana-Farber Cancer Institute · Boston, Massachusetts and 1 other locations · NCT06321484

• Combining revumenib with standard chemotherapy and targeted therapy for acute myeloid leukemia

  This study is testing a new treatment combining revumenib with standard chemotherapy and another targeted therapy to see if it helps newly diagnosed patients with a specific type of acute myeloid leukemia.

  Recruiting at 2 sites Phase 1 Dana-Farber Cancer Institute · New Haven, Connecticut and 1 other locations · NCT06313437

• Feasibility of the PediRISE program for families of children with cancer

  This study is testing a support program for families of children recently diagnosed with cancer who are struggling financially to see if it helps them better than regular care.

  Recruiting at 4 sites Dana-Farber Cancer Institute · San Francisco, California and 3 other locations · NCT06283251

• Combination treatment for advanced head and neck cancer

  This study is testing a new combination treatment for people with advanced head and neck cancer to see if it can boost their immune response and help fight the disease.

  Recruiting at 2 sites Phase 2 Dana-Farber Cancer Institute · Boston, Massachusetts and 1 other locations · NCT06239220

• Managing cardiovascular risks in prostate cancer patients starting hormone therapy

  This study is testing a program to help men with prostate cancer manage heart health risks when they start hormone therapy.

  Recruiting at 2 sites Dana-Farber Cancer Institute · Boston, Massachusetts and 1 other locations · NCT06202820

• Exercise program for young patients with colorectal cancer undergoing chemotherapy

  This study is testing whether an exercise program can help young patients with colorectal cancer feel better during chemotherapy and improve their treatment results.

  Recruiting Dana-Farber Cancer Institute · Boston, Massachusetts · NCT06202183

• Datopotamab deruxtecan for treating breast cancer that has spread to the brain

  This study is testing a new drug called datopotamab deruxtecan to see if it can help people with HER2-negative breast cancer that has spread to the brain.

  Recruiting at 3 sites Phase 2 Dana-Farber Cancer Institute · Miami, Florida and 2 other locations · NCT06176261

• CIML NK cells combined with venetoclax for treating acute myeloid leukemia

  This study is testing a new treatment using special immune cells and a medication to see if it can help people with acute myeloid leukemia feel better.

  Recruiting at 2 sites Phase 1 Dana-Farber Cancer Institute · Boston, Massachusetts and 1 other locations · NCT06152809

• CIML NK cell therapy to prevent relapse after stem cell transplant

  This study is testing if a new type of immune cell therapy can help prevent relapse in people with certain blood cancers after they receive a stem cell transplant.

  Recruiting Phase 1 Dana-Farber Cancer Institute · Boston, Massachusetts and 1 other locations · NCT06138587

• Understanding treatment for older patients with advanced bladder cancer

  This study is testing a new way to help older patients with advanced bladder cancer who can't take certain chemotherapy drugs by using a survey to see how well treatments work and how they affect their quality of life.

  Recruiting Dana-Farber Cancer Institute · Boston, Massachusetts · NCT06138561

• Screening for pancreatic cancer in high-risk individuals

  This study is testing if combining blood tests and symptom checks with regular screenings can help find pancreatic cancer earlier in people who are at higher risk because of their genetics.

  Recruiting Early Phase 1 Dana-Farber Cancer Institute · Boston, Massachusetts and 1 other locations · NCT06122896

• Integrated Smartphone Tool to Help Manage Malignant Pain

  A smartphone app called I-STAMP is being tested to help adults with advanced cancer see if it can better manage their pain and track their medications.

  Recruiting Dana-Farber Cancer Institute · Boston, Massachusetts · NCT06117709

• Evaluating Glofitamab Alone or with Other Treatments for Richter's Transformation

  This study is testing if a new treatment called Glofitamab, alone or with other medications, can help people with Richter's Transformation from Chronic Lymphocytic Leukemia feel better.

  Recruiting at 5 sites Phase 2 Dana-Farber Cancer Institute · Atlanta, Georgia and 4 other locations · NCT06043674

• Exercise program to improve health in men with metastatic prostate cancer

  This study is testing whether a 16-week exercise program can help men with metastatic prostate cancer feel stronger and healthier while they are receiving treatment.

  Recruiting Dana-Farber Cancer Institute · Boston, Massachusetts and 2 other locations · NCT06040125

• Helping young cancer survivors manage stress and build resilience

  This study is testing a program that helps young cancer survivors manage stress and build resilience through coaching and education delivered via a mobile app or video.

  Recruiting Dana-Farber Cancer Institute · Boston, Massachusetts and 1 other locations · NCT06038318

• Examining exercise training effects during immunotherapy in lung cancer patients

  This study is testing whether a 12-week exercise program can help people with advanced lung cancer feel better while they are receiving immunotherapy.

  Recruiting Dana-Farber Cancer Institute · Boston, Massachusetts · NCT06026111

• Combining pembrolizumab with CAR T-cell therapy for recurrent primary mediastinal large B-cell lymphoma

  This study is testing if adding pembrolizumab to CAR T-cell therapy can help people with recurrent primary mediastinal large B-cell lymphoma feel better and live longer.

  Recruiting at 2 sites Phase 2 Dana-Farber Cancer Institute · Boston, Massachusetts and 1 other locations · NCT05934448

• Using belumosudil to prevent or treat bronchiolitis obliterans in stem cell transplant patients

  This study is testing if a new medication called belumosudil can help prevent or treat bronchiolitis obliterans in patients who have recently had a stem cell transplant.

  Recruiting at 4 sites Phase 2 Dana-Farber Cancer Institute · Stanford, California and 5 other locations · NCT05922761

• Glofitamab and Polatuzumab with R-CHP for high-risk diffuse large B-cell lymphoma

  This will test whether adding the immunotherapies glofitamab and polatuzumab to standard R-CHP chemotherapy helps adults with previously untreated high-risk diffuse large B-cell lymphoma.

  Recruiting at 3 sites Phase 2 Dana-Farber Cancer Institute · Miami, Florida and 2 other locations · NCT05800366

• Testing a new drug combination for HER2-positive inflammatory breast cancer

  This study is testing a new combination of two drugs to see if they can safely and effectively treat people with stage III HER2-positive inflammatory breast cancer who haven't had treatment before.

  Recruiting at 3 sites Phase 2 Dana-Farber Cancer Institute · Boston, Massachusetts and 2 other locations · NCT05795101

• Epcoritamab plus rituximab as first treatment for follicular lymphoma

  This trial tests whether adding epcoritamab to rituximab is safe and effective as the first treatment for adults with untreated follicular lymphoma.

  Recruiting at 6 sites Phase 2 Dana-Farber Cancer Institute · Boston, Massachusetts and 5 other locations · NCT05783609

• CB-103 combined with lenvatinib or abemaciclib for NOTCH-activated adenoid cystic carcinoma

  This study tests whether combining the NOTCH inhibitor CB-103 with either lenvatinib or abemaciclib can slow tumor growth in adults with NOTCH-activated advanced or metastatic adenoid cystic carcinoma.

  Recruiting Phase 1/2 Dana-Farber Cancer Institute · Boston, Massachusetts · NCT05774899

• Comparing two prostate cancer treatments for quality of life

  This study is testing whether two prostate cancer treatments, Relugolix and Leuprolide, can help improve the quality of life for men with localized or recurring prostate cancer.

  Recruiting at 2 sites Phase 2 Dana-Farber Cancer Institute · Boston, Massachusetts and 2 other locations · NCT05765500

• High-Intensity Interval Exercise for Young Adult Survivors of Pediatric Brain Tumors

  This study is testing whether a 16-week online high-intensity exercise program can improve the physical and mental health of young adult survivors of childhood brain tumors.

  Recruiting Dana-Farber Cancer Institute · Boston, Massachusetts · NCT05740839

• Combination of immunotherapy and chemotherapy for head and neck cancer treatment

  This study is testing if combining an immunotherapy drug with chemotherapy before and after surgery can help people with head and neck cancer do better.

  Recruiting Phase 2 Dana-Farber Cancer Institute · Boston, Massachusetts and 1 other locations · NCT05726370

• Exercise program for multiple myeloma patients before stem cell transplant

  This study tests if a home-based exercise program can help people with multiple myeloma get stronger and healthier before they have a stem cell transplant.

  Recruiting at 2 sites Dana-Farber Cancer Institute · Boston, Massachusetts and 1 other locations · NCT05706766

• Combining VS-6766, Abemaciclib, and Fulvestrant for HR+/HER2-negative Breast Cancer

  This study is testing if a new drug called VS-6766, when combined with two other medications, can help people with hormone receptor-positive and HER2-negative metastatic breast cancer feel better.

  Recruiting at 2 sites Phase 1/2 Dana-Farber Cancer Institute · Boston, Massachusetts and 2 other locations · NCT05608252

• Understanding inherited risk factors for lung cancer

  This study is trying to understand how genetic factors affect the risk of lung cancer in people with little tobacco exposure, especially those with family histories of the disease.

  Recruiting Dana-Farber Cancer Institute · Boston, Massachusetts and 1 other locations · NCT05587439

• Telehealth exercise program for older women with breast cancer

  This study is testing if a telehealth exercise program with protein support can help older women with breast cancer feel better during and after chemotherapy compared to a regular health education program.

  Recruiting at 4 sites Dana-Farber Cancer Institute · Boston, Massachusetts and 3 other locations · NCT05535192

• Treatment for male breast cancer using endocrine therapy

  This study is testing different combinations of hormone therapy for men with early to mid-stage breast cancer to see which one works best compared to the usual treatment.

  Recruiting at 9 sites Phase 2 Dana-Farber Cancer Institute · Washington D.C., District of Columbia and 8 other locations · NCT05501704

• Testing Teclistamab for high-risk smoldering multiple myeloma

  This study is testing if Teclistamab can work better than a mix of Lenalidomide and Dexamethasone for people with high-risk smoldering multiple myeloma.

  Recruiting at 3 sites Phase 2 Dana-Farber Cancer Institute · Denver, Colorado and 2 other locations · NCT05469893

• Collecting data to predict cancer risk in at-risk populations

  This study is trying to collect samples and health information from people at higher risk of cancer to see if they can find signs that help predict cancer early on.

  Recruiting Dana-Farber Cancer Institute · Boston, Massachusetts · NCT05463796

• Improving access to cancer trials for underrepresented minorities

  This study is trying out a new program to help people from underrepresented backgrounds with advanced cancers learn about and access genomic testing for clinical trials.

  Recruiting at 2 sites Dana-Farber Cancer Institute · Boston, Massachusetts and 2 other locations · NCT05375643

• Resistance exercise and protein supplementation for pancreatic cancer patients

  This study is testing if a combination of resistance exercise and protein supplements can help pancreatic cancer patients starting chemotherapy improve their muscle mass, physical function, and overall quality of life.

  Recruiting Dana-Farber Cancer Institute · Boston, Massachusetts · NCT05356117

• Using light therapy to prevent mouth sores in patients getting stem cell transplants

  This study is testing if a special light therapy can help prevent mouth sores in patients getting stem cell transplants.

  Recruiting Dana-Farber Cancer Institute · Boston, Massachusetts · NCT05335434

• Exercise program to improve heart health in Black men with prostate cancer on hormone therapy

  This study is testing whether a special exercise program can help improve heart health and overall well-being in Black men with prostate cancer who are receiving hormone therapy.

  Recruiting Dana-Farber Cancer Institute · Boston, Massachusetts · NCT05327465

• Venetoclax treatment for high-risk blood cancers in young patients

  This study is testing a new combination of a drug called venetoclax with chemotherapy to see if it helps young patients with high-risk blood cancers feel better while keeping side effects low.

  Recruiting at 5 sites Phase 1 Dana-Farber Cancer Institute · San Francisco, California and 4 other locations · NCT05292664

• Understanding lung cancer in young adults

  This study is trying to learn more about the causes of lung cancer in young adults under 45 to help improve how we screen and treat this rare condition.

  Recruiting at 2 sites Dana-Farber Cancer Institute · Boston, Massachusetts and 3 other locations · NCT05265429

• Combination of zanubrutinib and venetoclax for treating chronic lymphocytic leukemia

  This study is testing if combining the drugs zanubrutinib and venetoclax can help adults with chronic lymphocytic leukemia who have already been treated feel better and manage their disease.

  Recruiting at 4 sites Phase 2 Dana-Farber Cancer Institute · Scarborough, Maine and 3 other locations · NCT05168930

• Exercise program to help cancer patients during chemotherapy

  This study tests if a 16-week online exercise program can help women with ovarian or endometrial cancer feel better during their first round of chemotherapy.

  Recruiting Dana-Farber Cancer Institute · Boston, Massachusetts · NCT04997096

• Using scalp cooling to prevent hair loss in metastatic breast cancer patients

  This study is testing if using a scalp cooling system during chemotherapy can help prevent hair loss in people with metastatic breast cancer.

  Recruiting at 2 sites Phase 2 Dana-Farber Cancer Institute · Boston, Massachusetts and 1 other locations · NCT04986579

• Genomic profiling of blood and bone marrow samples from children and young adults with blood cancers

  This study is testing how analyzing the genes in blood and bone marrow samples from kids and young adults with blood cancers can help doctors make better treatment decisions.

  Recruiting at 6 sites Dana-Farber Cancer Institute · Hartford, Connecticut and 7 other locations · NCT04968834

• Testing Paxalisib for recurrent primary central nervous system lymphoma

  This study is testing a new drug called Paxalisib to see if it can help people with recurrent primary central nervous system lymphoma feel better and manage their condition.

  Recruiting Phase 2 Dana-Farber Cancer Institute · Boston, Massachusetts and 1 other locations · NCT04906096

• Tailored treatment for HPV-positive oropharyngeal cancer using blood tests

  This study is testing a new way to tailor treatment for people with HPV-related throat cancer by using blood tests to see if adjusting their radiation and chemotherapy can improve their outcomes.

  Recruiting at 2 sites Phase 2 Dana-Farber Cancer Institute · Boston, Massachusetts and 1 other locations · NCT04900623

• Comparing two treatments for early-stage HER2-positive breast cancer after surgery

  This study is testing whether a new treatment combining T-DM1 and trastuzumab can help people with early-stage HER2-positive breast cancer feel better and live longer after surgery compared to a standard treatment.

  Recruiting at 46 sites Phase 2 Dana-Farber Cancer Institute · San Francisco, California and 52 other locations · NCT04893109

• Early treatment of metastatic adenoid cystic carcinoma with focused radiation therapy

  This study is testing if starting focused radiation therapy early can help people with a specific type of cancer that has spread to a few places feel better and live longer compared to standard treatment.

  Recruiting at 5 sites Dana-Farber Cancer Institute · San Francisco, California and 4 other locations · NCT04883671

• Combination treatment for mantle cell lymphoma

  This study is testing a combination of three drugs to see if they can help people with mantle cell lymphoma that has come back or hasn't been treated yet.

  Recruiting at 3 sites Phase 1/2 Dana-Farber Cancer Institute · Chicago, Illinois and 2 other locations · NCT04855695

• Combining weight loss surgery with hysterectomy for obese women with endometrial cancer

  This study is testing whether combining weight loss surgery with a hysterectomy can help obese women with endometrial cancer get better results and improve their health.

  Recruiting at 2 sites Dana-Farber Cancer Institute · Boston, Massachusetts and 1 other locations · NCT04839614

• Using nanoparticles with MR-guided radiation therapy for lung and pancreatic tumors

  This study is testing if a new type of nanoparticle can make radiation therapy more effective for people with lung tumors and advanced pancreatic cancer.

  Recruiting at 2 sites Phase 1/2 Dana-Farber Cancer Institute · Boston, Massachusetts and 1 other locations · NCT04789486

• Sacituzumab govitecan plus enfortumab vedotin for metastatic urothelial cancer

  This trial tests whether combining sacituzumab govitecan and enfortumab vedotin, with pembrolizumab in some patients, helps people with metastatic urothelial carcinoma who have progressed after platinum chemotherapy and PD‑1/PD‑L1 inhibitors.

  Recruiting Phase 1/2 Dana-Farber Cancer Institute · Boston, Massachusetts · NCT04724018

• New approach to stem cell transplant for high-risk leukemia patients

  This study is testing a new type of stem cell transplant for high-risk leukemia patients to see if it can help them recover better and avoid complications.

  Recruiting Phase 1 Dana-Farber Cancer Institute · Boston, Massachusetts · NCT04678401

• Improving cancer care for older adults with gastrointestinal cancers

  This study is testing a new way to improve cancer care for older adults with gastrointestinal cancers by adding special consultations to their treatment plans.

  Recruiting Dana-Farber Cancer Institute · Boston, Massachusetts · NCT04674267

• Improving treatment for inflammatory breast cancer

  This study is testing if using a special dye and a radioactive substance can help doctors find important lymph nodes during surgery for people with inflammatory breast cancer.

  Recruiting Dana-Farber Cancer Institute · Boston, Massachusetts · NCT04636710

• Tracking daily steps in older thoracic surgery patients

  This study tests whether older patients having thoracic surgery are willing to wear a Fitbit to track their daily steps in the week before their surgery.

  Recruiting at 2 sites Dana-Farber Cancer Institute · Boston, Massachusetts and 1 other locations · NCT04630496

• Using T-DM1 with chemotherapy and radiation for HER2-positive salivary gland cancer after surgery

  This study is testing if adding a new drug called T-DM1 to regular chemotherapy and radiation can help people with HER2-positive salivary gland cancer stay cancer-free after surgery.

  Recruiting at 13 sites Phase 2 Dana-Farber Cancer Institute · Atlanta, Georgia and 12 other locations · NCT04620187

• Understanding Li-Fraumeni Syndrome and TP53 Variants

  This study is trying to understand cancer risks in people with Li-Fraumeni Syndrome or TP53 gene changes to help improve prevention and treatment options.

  Recruiting at 3 sites Dana-Farber Cancer Institute · Boston, Massachusetts and 2 other locations · NCT04541654

• Testing Sacituzumab Govitecan with or without Pembrolizumab for metastatic triple-negative breast cancer

  This study is testing whether a new cancer drug called Sacituzumab Govitecan, alone or with another drug called Pembrolizumab, can help people with metastatic triple-negative breast cancer that hasn't been treated before.

  Recruiting at 15 sites Phase 2 Dana-Farber Cancer Institute · Stamford, Connecticut and 14 other locations · NCT04468061

• Atezolizumab and sacituzumab govitecan to prevent recurrence in triple-negative breast cancer

  This trial tests whether combining sacituzumab govitecan with atezolizumab can prevent cancer from coming back in people with triple-negative breast cancer who have residual disease after pre-surgery chemotherapy and detectable circulating tumor DNA.

  Recruiting at 4 sites Phase 2 Dana-Farber Cancer Institute · San Francisco, California and 6 other locations · NCT04434040

• Combination therapy for recurrent primary central nervous system lymphoma

  This study is testing a new combination of three medications to see if it can help people with recurrent primary central nervous system lymphoma feel better after their previous treatments didn't work.

  Recruiting at 3 sites Phase 1/2 Dana-Farber Cancer Institute · Boston, Massachusetts and 3 other locations · NCT04421560

• Using MRI scans to monitor cancer treatment response during radiation therapy

  This study is testing if regular MRI scans can help doctors see how well radiation therapy is working for patients with advanced cancers like glioblastoma and esophageal cancer.

  Recruiting at 2 sites Dana-Farber Cancer Institute · Boston, Massachusetts and 1 other locations · NCT04188535

• Using pembrolizumab to treat pediatric liver cancer

  This study is testing if the immunotherapy drug pembrolizumab can help children and young adults with liver cancer feel better and improve their condition.

  Recruiting at 5 sites Phase 2 Dana-Farber Cancer Institute · San Francisco, California and 4 other locations · NCT04134559

• Using MRI to guide radiation therapy for various cancers

  This study is testing if using MRI scans to adjust radiation therapy can help people with different types of cancer, like pancreatic and lung cancer, feel better and control their tumors more effectively.

  Recruiting at 2 sites Dana-Farber Cancer Institute · Boston, Massachusetts and 1 other locations · NCT04115254

• Testing a microdevice for drug screening in skin lesions of T-cell lymphoma

  This study is testing a small device that delivers cancer drugs directly into skin lesions to see if it helps people with cutaneous T-cell lymphoma or peripheral T-cell lymphoma.

  Recruiting Dana-Farber Cancer Institute · Boston, Massachusetts · NCT04045470

• Understanding Chronic Lymphocytic Leukemia

  This study is collecting tissue samples and medical information from people with Chronic Lymphocytic Leukemia to see what causes the disease and find better treatments.

  Recruiting Dana-Farber Cancer Institute · Boston, Massachusetts · NCT04028531

• CIML NK cell infusion for relapsed myeloid disease after stem cell transplant

  This trial tests whether giving cytokine‑induced memory‑like (CIML) natural killer cells together with low‑dose IL‑2 can help adults (≥18) and teens (≥12) whose AML, MDS, MPN, or JMML has returned after a stem cell transplant.

  Recruiting at 2 sites Phase 1 Dana-Farber Cancer Institute · Boston, Massachusetts and 1 other locations · NCT04024761

• Lowering radiation and chemotherapy after surgery for HPV-related throat cancer

  This study is testing if giving less radiation and chemotherapy after surgery can still effectively treat people with HPV-related throat cancer while reducing side effects and improving their quality of life.

  Recruiting Dana-Farber Cancer Institute · Boston, Massachusetts · NCT03875716

• Evaluating new methods for staging and prognosis in malignant pleural mesothelioma

  This study is testing a new way to better understand the stage and outlook of malignant pleural mesothelioma by looking at tissue samples from patients to help doctors make more informed treatment decisions.

  Recruiting Dana-Farber Cancer Institute · Boston, Massachusetts · NCT03683680

• Abemaciclib plus letrozole with optional metformin, zotatifin, or gedatolisib for ER-positive endometrial and low-grade serous ovarian cancer

  This treatment plan tests whether adding the CDK4/6 drug abemaciclib to the hormone drug letrozole, with or without metformin, zotatifin, or gedatolisib, can help people with ER-positive endometrial cancer or low-grade serous ovarian cancer.

  Recruiting at 3 sites Phase 2 Dana-Farber Cancer Institute · Boston, Massachusetts and 2 other locations · NCT03675893

• Combination treatment for BCR-ABL positive B-cell leukemia and chronic myeloid leukemia

  This study is testing a new combination treatment for people with BCR-ABL positive B-cell leukemia or chronic myeloid leukemia to see if it helps them feel better and works well with existing medications.

  Recruiting at 4 sites Phase 1 Dana-Farber Cancer Institute · Chicago, Illinois and 3 other locations · NCT03595917

• Using Abemaciclib to treat certain cancers with specific genetic changes

  This study is testing if a new cancer drug called Abemaciclib can help people with advanced tumors that have certain genetic changes slow down or stop their cancer growth.

  Recruiting Phase 2 Dana-Farber Cancer Institute · Boston, Massachusetts · NCT03310879

• Personalized vaccine for treating chronic lymphocytic leukemia

  This study is testing a new personalized cancer vaccine for people with chronic lymphocytic leukemia who haven't had treatment yet, to see how well it works and if it's safe.

  Recruiting Phase 1 Dana-Farber Cancer Institute · Boston, Massachusetts · NCT03219450

• Combining SL-401 with Azacitidine or Venetoclax for treating blood cancers

  This study is testing if combining a new treatment called SL-401 with existing drugs azacitidine or venetoclax can help people with certain blood cancers feel better and improve their outcomes.

  Recruiting at 3 sites Phase 1 Dana-Farber Cancer Institute · Duarte, California and 2 other locations · NCT03113643

• Individualized treatment for Glioblastoma using new drugs

  This study is testing new drugs for people with glioblastoma to see if they work better than the standard treatment.

  Recruiting at 4 sites Phase 2 Dana-Farber Cancer Institute · Birmingham, Alabama and 11 other locations · NCT02977780

• Understanding genetic risks for thyroid cancer

  This study is trying to find out if certain genes passed down in families can increase the risk of thyroid cancer by looking at the family and medical histories of people with thyroid cancer or nodules.

  Recruiting Dana-Farber Cancer Institute · Boston, Massachusetts · NCT02747888

• Assessing molecular changes in blood cancers

  This study is trying to see how changes in blood samples from people with early blood cancers can help us understand their condition better and find new treatment options.

  Recruiting at 7 sites Dana-Farber Cancer Institute · Boston, Massachusetts and 6 other locations · NCT02269592

• Using vitamin D to treat colon cancer

  This study tests if taking high doses of vitamin D before surgery can help people with early-stage colon cancer or liver metastases feel better and improve their treatment outcomes.

  Recruiting Early Phase 1 Dana-Farber Cancer Institute · Boston, Massachusetts · NCT02172651

• Creating a tumor bank for families with multiple blood cancers

  This study is trying to collect samples from families with multiple blood cancers to see if there are specific genetic factors that make them more likely to develop lymphomas.

  Recruiting Dana-Farber Cancer Institute · Boston, Massachusetts · NCT00131014

Quick answers

How many clinical trials run by Dana-Farber Cancer Institute are recruiting right now?

150, as of November 12, 2026. We update this list each time we refresh our data from ClinicalTrials.gov.

Where are these trials running?

All of them have sites in United States. Each study page lists its sites and which ones are recruiting.

What phases are they in?

Phase 2: 47, Phase 1: 21, Phase 1/2: 12, Early Phase 1: 5. Trials with no phase listed are usually device, behavioural or observational studies.

How do I join one?

Open a study, check the "Is this trial a fit for you?" section, then contact the study team listed on the page. They will ask a few screening questions. Asking is free and does not commit you to anything. Talk it over with your doctor first.

Find the studies that fit you

A list is a starting point. Tell us your situation in your own words and we'll rank the studies that match and explain why. It's free and needs no account.

Describe your situation →